IP Library › Granted Patent US 9,468,639
Granted Patent B2
US 9,468,639 · App. 14/640,055 · Granted Oct 18, 2016

Treating sexual desire disorders with flibanserin

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,468,639
App. No.
14/640,055
Granted
Oct 18, 2016
Kind
B2
Abstract

The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.

Claims (20)

1. A method of treating decreased sexual desire in a patient, comprising administering a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to the patient to treat decreased sexual desire.

2. The method according to claim 1 , wherein the patient is female.

3. The method according to claim 1 , wherein the patient is male.

4. The method according to claim 1 , wherein the amount administered is between about 0.1 mg and 400 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

5. The method according to claim 1 , wherein the amount administered is between about 1 mg and 300 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

6. The method according to claim 1 , wherein the amount administered is in a dosage unit containing between about 0.01 mg and 100 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

7. The method according to claim 1 , wherein the amount administered is in a dosage unit containing between about 0.1 mg and 50 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

8. A method of treating absent sexual desire in a patient, comprising administering a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to the patient to treat decreased sexual desire.

9. The method according to claim 8 , wherein the patient is female.

10. The method according to claim 8 , wherein the patient is male.

11. The method according to claim 8 , wherein the amount administered is between about 2 mg and 200 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

12. The method according to claim 8 , wherein the amount administered is between about 0.1 mg and 100 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

13. The method according to claim 8 , wherein the amount administered is in a dosage unit containing about 150 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

14. A method of treating inhibited sexual desire in a patient, comprising administering a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to the patient to treat decreased sexual desire.

15. The method according to claim 14 , wherein the patient is female.

16. The method according to claim 14 , wherein the patient is male.

17. The method according to claim 14 , wherein the amount administered is between about 0.1 mg and 400 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

18. The method according to claim 14 , wherein the amount administered is in a dosage unit containing about 100 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

19. The method according to claim 14 , wherein the amount administered is in a dosage unit containing about 80 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

20. The method according to claim 14 , wherein the amount administered is in a dosage unit containing about 50 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Sep 9, 2022
From: BARCLAYS BANK PLC
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061402/0194 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Sep 9, 2022
From: THE BANK OF NEW YORK MELLON
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061402/0236 →
SECURITY INTEREST Recorded Feb 25, 2021
From: SPROUT PHARMACEUTICALS, INC.
To: GOODRICH, BRAXTON; WHITEHEAD, ROBERT
Reel/Frame 055407/0810 →
SECURITY INTEREST Recorded Jul 19, 2017
From: SPROUT PHARMACEUTICALS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0950 →
SECURITY AGREEMENT Recorded Dec 21, 2015
From: SPROUT PHARMACEUTICALS, INC., AS GRANTOR; UNILENS VISION INC., AS GRANTOR; COMMONWEALTH LABORATORIES, LLC, AS GRANTOR; SYNERGETICS USA, INC., AS GRANTOR
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 037357/0490 →